pelabresib

News

Novartis sheds MorphoSys staff, sites after pelabresib delay

Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.

News

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around

News

MorphoSys shrugs off mixed results for myelofibrosis drug

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.

Novartis sheds MorphoSys staff, sites after pelabresib delay

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

MorphoSys shrugs off mixed results for myelofibrosis drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks